Dermatology World March 2011 : Page 11

Proven effective in moderate to severe acne 1,2 Power To treat ● To please ● With ease! ● ● In studies with more than 2800 patients with moderate to severe acne, Acanya®Gel demonstrated: 64% median reduction in infl ammatory lesion counts at 12 weeks (34% for vehicle) 1,2 49% median reduction in noninfl ammatory lesion counts at 12 weeks (26% for vehicle) 1,2 No patient treated with Acanya Gel discontinued treatment due to erythema, scaling, burning, stinging, or itching in pivotal trials 1 Low potential for cutaneous irritation may lead to increased adherence to treatment Neat and simple: No jar, no mess No pharmacy admixing: Pump now replaces the Acanya Gel jar Measured dose: Consistent delivery ● ● ● Indication and Important Safety Information Acanya Gel is indicated for the topical treatment of acne vulgaris in patients 12 years of age or older. Acanya Gel is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. Discontinuation is recommended if signifi cant diarrhea develops. In controlled clinical trials, the following application-site adverse reactions occurred in less than 0.2% of patients treated with Acanya Gel: application-site pain (0.1%), application-site exfoliation (0.1%), and application-site irritation (0.1%). Of the patients who experienced cutaneous symptoms of erythema, scaling, itching, burning, and/or stinging, regardless of the relationship to therapy, the majority of cases were mild to moderate in severity, occurred early in treatment, and decreased thereafter. Now in a ready-to-use 50g pump for your patients’ convenience To learn more, please visit www.AcanyaGel.com Please see the following page for references and brief summary of full prescribing information. © 2010 CORIA Laboratories ACAN-0510-6004 Acanya Gel Disp: 50g Sig: Apply to affected area once daily ® 4 refills ACAN-1010-0002

Coria laboratories

 

Loading